Wyniki wyszukiwania

1

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Characteristics of selected second-generation antiepileptic drugs used in dogs

100%

Ziolkowski H., Jaroszewski J. J., Ziolkowska N., Jasiecka A.

Polish Journal of Veterinary Sciences

|

2012

|

tom 15

|

nr 3

A significant number of cases of clinical canine epilepsy remain difficult to control in spite of the applied treatment. At the same time, the range of antiepileptic drugs is increasingly wide, which allows efficient treatment. In the present paper we describe the pharmacodynamics and pharmacokinetics of the newer antiepileptic drugs which were licensed after 1990 but are still not widely used in veterinary medicine. The pharmacokinetic profiles of six of these drugs were tested on dogs. The results of experimental studies suggest that second generation antiepileptic drugs may be applied in mono- as well as in poli- treatment of canine epilepsy because of the larger safety margin and more advantageous pharmacokinetic parameters. Knowledge of the drugs’ pharmacokinetics allows its proper clinical appliance, which, in turn, gives the chance to improve the efficiency of pharmacotherapy of canine epilepsy.

2

Comparative pharmacokinetics of free and liposome-encapsulated ampicillin after intravenous and subcutaneous administrations

100%

Yapar K., Bas A. L.

Bulletin of the Veterinary Institute in Puławy

|

2004

|

tom 48

|

nr 4

3

Pharmacokinetics of flunixin-meglumin following intravenous administration in Angora rabbits

100%

Elmas M., Uney K., Karabacak A., Yazar E.

Bulletin of the Veterinary Institute in Puławy

|

2005

|

tom 49

|

nr 1

4

The study of interactions between ibuprofen and bovine serum albumin

86%

Jasinska A., Ferguson A., Mohamed W. S., Szreder T.

Zeszyty Naukowe. Politechnika Łódzka. Chemia Spożywcza i Biotechnologia

|

2009

|

tom 73

15-24

5

Effect of piperine, a major component of black pepper, on the pharmacokinetics of domperidone in rats

86%

Alhumayyd M. S., Bukhari I. A., Almotrefi A. A.

Journal of Physiology and Pharmacology

|

2014

|

tom 65

|

nr 6

6

Pharmacokinetics of flunixin in mature heifers following multiple intravenous administration

86%

Jaroszewski J., Jedziniak P., Markiewicz W., Grabowski T., Chrostowska M., Szprengier-Juszkiewicz T.

Polish Journal of Veterinary Sciences

|

2008

|

tom 11

|

nr 3

199-203

The pharmacokinetics of flunixin meglumine was determined after its multiple (altogether 4 doses at 24-hours intervals) intravenous administration at a dose of 2.2 mg/kg body weight in six mature clinically healthy heifers. Plasma flunixin and its metabolite 5-hydroxyflunixin concentrations were analyzed with high-pressure liquid chromatography using an assay with a lower limit detection of 0.03 μg/ml for both substances. Plasma concentrations versus time curves were described by a two compartment open model. Mean plasma flunixin concentrations were similar on day 1 and 4, and than rapidly decreased (within 2 hours) from initial concentrations higher than 10 μg/ml to the concentrations lower than 1 μg/ml. The distribution phase of flunixin was short (t05α = 0.29 ± 0.16 and 0.18 ± 0.04 on day 1 and 4, respectively) and the elimination phase was more prolonged (t05ß = 3.30 + 0.60 and 3.26 + 0.22 on day 1 and 4, respectively). The mean residence time of flunixin was similar on day 1 (1.83 ± 0.83) and 4 (1.88 + 0.46), and for 5-hydroxyflunixin this parameter was insignificantly (P > 0.05) higher on day 1 (5.49 ± 2.22) as compared to that found on day 4 (3.99 ± 2.17). The clearance of flunixin was similar on both examined days (0.23 ± 0.12 on day 1 and 0.31 ± 0.15 on day 4), and for 5-hydroxyflunixin was insignificantly (P > 0.05) lower on day 1 (2.37 ± 1.21) as compared to that determined on day 4 (3.23 ± 1.06). Our data indicate that multiple administration of flunixin did not alter significantly the parent drug and its metabolite concentrations in plasma, however may cause some small changes in pharmacokinetic parameters.

7

Diagnostic utility and pharmacokinetics of PEG-liposomes

86%

Storm G., Dams E. T. M., Oijen W. J. G., Oussoren C. O., Corstens F. H. M., Laverman P., Boerman O. C.

Cellular and Molecular Biology Letters

|

1999

|

tom 04

|

nr 2

8

2-chloro-2'-deoxyadenosine - clinical, biochemical and pharmacokinetic considerations

86%

Liliemark J., Juliusson G.

Archivum Immunologiae et Therapiae Experimentalis

|

1994

|

tom 42

|

nr 1

9

Influence of experimentally induced toxoplasmosis [Toxoplasma gondii] on the pharmacokinetics of levofloxacin

86%

Yarsan E., Tanyuksel M., Koc F., Essiz D., Babur C.

Bulletin of the Veterinary Institute in Puławy

|

2003

|

tom 47

|

nr 2

10

In vivo cardioprotective effects and pharmacokinetic profile of N-propyl caffeamide against ischemia reperfusion injury

72%

Cheng Y.-Y., Luo D., Xia Z., Tse H.-F., Li X., Rong J.

Archivum Immunologiae et Therapiae Experimentalis

|

2017

|

tom 65

|

nr 2

11

BonisteinTM (synthetic genistein), a food component in development for a bone health nutraceutical

72%

Ullmann U., Bendik I., Fluhmann B.

Journal of Physiology and Pharmacology. Supplement

|

2005

|

tom 56

|

nr 1

79-95

In the discussion of the risk-benefit relation of the hormone replacement therapy (HRT) for elder women phytochemicals with estrogenic activity received a great deal of attention. Phytoestrogens are naturally occurring compounds with structural similarity to 17b-estradiol. Especially genistein, an isoflavone most abundant in soy, possess a high and selective binding-affinity to the mammalian estrogen receptors. It has been found, that genistein exert in humans both: weak estrogenic and antiestrogenic effects, similar to the SERMs. Consequently, it was concluded, that genistein might provide an alternative to prevent postmenomausal bone-loss and ameliorate menopausal symptoms without side-effects similar to HRT. Pre-clinical experiments and results from clinical pilot studies with pure genistein confirmed its efficacy in these indications. Nevertheless, currently some open issues still exist to recommend its intake thoughtlessly. Bonistein, pure synthetic genistein developed by DSM Nutritional Products, was tested extensively in appropriate models for bone health. A battery of toxicological studies was conducted to determine safe intake levels. In the early clinical development pharmacokinetic studies were performed in healthy volunteers and in postmenopausal women. Now large-scale studies are in preparation to investigate Bonistein's efficacy in postmenopausal bone-loss and climacteric syndrome.

12

Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats

72%

Lim T. H., Cho Y. A., Choi D. H.

Journal of Physiology and Pharmacology

|

2015

|

tom 66

|

nr 4

13

Pharmacokinetics of tramadol and metabolites after injective administrations in dogs

72%

Giorgi M., Del Carlo S., Lebkowska-Wieruszewska B., Kowalski C. J., Saccomanni G.

Polish Journal of Veterinary Sciences

|

2010

|

tom 13

|

nr 4

The aim of this study was to determine the pharmacokinetics of tramadol and its main metabolites after IV and IM injections. The pharmacokinetic cross-over study was carried out on 6 healthy male beagle dogs. Tramadol was administered by intravenous (IV) and intramuscular (IM) injection at 4 mg/kg. Tramadol and its main metabolites O-desmethyl-tramadol (M1), N-,N-didesmethyl-tramadol (M2) and N-,O-didesmethyl-tramadol (M5) concentrations were measured in plasma samples by a HPLC coupled with fluorimetric detection; pharmacokinetic evaluations were carried out with a compartmental and non-compartmental model for tramadol and its metabolites, respectively. The bioavailability of the drug, ranging between 84-102% (mean 92%), was within the generally accepted values for a positive bioequivalence decision of (80-125%). After the IM injection the mean plasma drug concentration peak was reached after a Tmax of 0.34 h with a Cmax of 2.52 μg/mL. No therapeutic relevant differences were observed between IM and IV administration. The minimal effective plasma concentration was reached after a few minutes and maintained for about 6-7 h in both administrations. M1 plasma concentration was low and the amounts of the other metabolites produced were analogous in both routes of administration. In conclusion, tramadol was rapidly and almost completely absorbed after IM administration and its systemic availability was equivalent to the IV injection. The different onset time and duration of action observed were very small and probably therapeutically irrelevant. The IM injection is a useful alternative to IV injection in the dog.

14

Molecular docking and prediction of ADME/drug-likeness properties of potentially active antidiabetic compounds isolated from aqueous-methanol extracts of Gymnema sylvestre and Combretum micranthum

72%

Ononamadu C. J., Ibrahim A.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2021

|

tom 102

|

nr 1

15

Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers

72%

Majcherczyk J., Kulza M., Senczuk-Przybylowska M., Florek E., Jawien W., Piekoszewski W.

Journal of Physiology and Pharmacology

|

2012

|

tom 63

|

nr 1

16

Pharmacokinetics of tylosin in broiler chickens

72%

Kowalski C., Rolinski Z., Zan R., Wawron W.

Polish Journal of Veterinary Sciences

|

2002

|

tom 05

|

nr 3

17

Evaluation of the bioequivalence of two erythromycin thiocyanate formulations after oral administration to broiler chickens

72%

Kowalski C. J., Pomorska-Mol M.

Bulletin of the Veterinary Institute in Puławy

|

2009

|

tom 53

|

nr 2

247-250

Twenty-one eight-week-old healthy broiler chickens of both sexes were used in the experiment. The birds were randomly allotted to three groups: two experimental (A and B) and one control. The chickens from group A received erythromycin in the form of granulate (Erytrowet® granulat), while the chickens from group B received erythromycin as a powder (Erytrowet®). Both formulations were administrated orally at a single dose of 25 mg/kg b.w. Blood samples were collected at 0.5, 1, 2, 2.5, 3, 4, 6, 8 and 12 h after administration of the drugs. Erythromycin concentrations were determined by the HPLC method. Comparison of the plasma pharmacokinetic profiles of both products indicated that there were no differences in the basic pharmacokinetic parameters between both formulations. The results indicate that the formulations used in this study are bioequivalent.

18

Molecular docking and pharmacokinetic prediction of phytochemicals from Syzygium cumini in interaction with penicillin-binding protein 2a and erythromycin ribosomal methylase of Staphylococcus aureus

72%

Shidiki A., Vyas A.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2022

|

tom 103

|

nr 1

19

Pharmacokinetics of antipyrine in calves at neonatal period fed with casein supplemented food

72%

Janus K.

Archivum Veterinarium Polonicum

|

1994

|

tom 34

|

nr 3-4

20

The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study

72%

Ishida T., Maeda R., Ichihara M., Mukai Y., Motoki Y., Manabe Y., Irimura K., Kiwada H.

Cellular and Molecular Biology Letters

|

2002

|

tom 07

|

nr 2

Ograniczanie wyników

Characteristics of selected second-generation antiepileptic drugs used in dogs

Comparative pharmacokinetics of free and liposome-encapsulated ampicillin after intravenous and subcutaneous administrations

Pharmacokinetics of flunixin-meglumin following intravenous administration in Angora rabbits

The study of interactions between ibuprofen and bovine serum albumin

Effect of piperine, a major component of black pepper, on the pharmacokinetics of domperidone in rats

Pharmacokinetics of flunixin in mature heifers following multiple intravenous administration

Diagnostic utility and pharmacokinetics of PEG-liposomes

2-chloro-2'-deoxyadenosine - clinical, biochemical and pharmacokinetic considerations

Influence of experimentally induced toxoplasmosis [Toxoplasma gondii] on the pharmacokinetics of levofloxacin

In vivo cardioprotective effects and pharmacokinetic profile of N-propyl caffeamide against ischemia reperfusion injury

BonisteinTM (synthetic genistein), a food component in development for a bone health nutraceutical

Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats

Pharmacokinetics of tramadol and metabolites after injective administrations in dogs

Molecular docking and prediction of ADME/drug-likeness properties of potentially active antidiabetic compounds isolated from aqueous-methanol extracts of Gymnema sylvestre and Combretum micranthum

Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers

Pharmacokinetics of tylosin in broiler chickens